MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...

The Semaglutide peptide has emerged as a compelling subject in biochemical and physiological research due to its potential ...

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

GLP-1RA use necessitated shifting priorities in nutrition and lifestyle modification among patients with obesity, according ...

Time CEO Austin Vanchieri Becomes Executive Chair NORTH CANTON, OHIO / ACCESS Newswire / July 1, 2025 / Visual Edge IT, Inc., ...

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...

Danish pharma giant Novo Nordisk’s announcement comes months after launch of another top selling obesity drug Mounjaro in ...

Semaglutide, a synthetic analog of glucagon-like peptide-1 (GLP-1), has garnered attention for its intriguing properties and potential implications in various r ...

Background: The use of glucagon-like peptide 1 receptor agonists (GLP-1RAs) has substantially expended given their remarkable benefits in managing obesity. Yet, their impact on long-term cancer risk ...

Background: Obesity is a major risk factor for cancer development. However, whether glucagon-like peptide-1 receptor agonists (GLP-1RAs), a class of diabetes medication which causes weight loss, ...